Bayesian Statistics Approach Offers Benefits To Sponsors, FDA Staffers Say
This article was originally published in The Gray Sheet
Use of Bayesian statistics in designing Guidant's Multi-Link Duet stent trial would have halved the number of enrollees required for FDA approval, according to Guidant Senior Biostatistician Frank Hu.
You may also be interested in...
FDA is encouraging medical device firms to consider using Bayesian estimation in clinical trials to streamline regulatory timeframes
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.